Newsletter | May 28, 2024

05.28.24 -- Understanding The New MHRA Requirements For Medical Devices In Great Britain

SPONSOR

New FDA QMSR: Its Role in Part 4 Compliance for Combination Products

The FDA’s release of the new Quality Management System Regulation (QMSR) significantly revises 21 CFR Part 820 Quality System Regulation and, in turn, Part 4 CGMP for combination products. Join us on June 26th as experts discuss the history and intentions of the new QMSR and what it means for combination product manufacturers and areas of risk your organization may need to address.

FEATURED EDITORIAL

Understanding The New MHRA Requirements For Medical Devices In Great Britain

The U.K.’s MHRA has updated its transition arrangement dates for CE marked devices with regard to EU MDR compliance.

INDUSTRY INSIGHTS

Nanoscale Technology's Potential: A Fireside Chat With Industry Leaders

Join industry experts in this fireside chat from Partnerships in Drug Delivery (PODD) to learn about the potential of nanoscale medicines and delivery devices to benefit patients.

Intranasal Drug Product Development — From Formulation To Scale-Up

Explore the key advantages of intranasal drug delivery, including its potential to rapidly treat conditions like migraines and headaches, and deliver medications directly to the brain.

Bridging Human Expertise And AI To Optimize Drug Delivery Solutions

Discover how leveraging AI's capabilities while relying on human expertise can optimize human performance in the healthcare sector and pave the way for a more efficient, effective healthcare system.

High Viscosity Formulations: A ‘Human Solution’ To Autoinjector Design

Delivering high viscosity (HV) formulations with a truly human solution involves a balance between safety and practicality. Learn the importance of achieving this solution with HV autoinjector design.

KinetiSol Technology: Scale Up Approach

Process parameter and quality attribute relationships, including those for typical pre and post KinetiSol unit operations, will be explored in the context of real-world examples.

Have You Ever Failed A Design Verification Test For Your Delivery Device?

If a drug delivery device fails a design verification test, the consequences can be lost revenue for the pharma company and delays for patients. Explore how to eliminate design verification failure.

Maintaining Drug Bioavailability And Masking Taste With Microencapsulation

Several technologies are available for microencapsulating drugs. Finding the right CDMO to optimize a drug’s efficacy and manufacturing during formulation is integral to its clinical and commercial success.

SOLUTIONS

Non-Viral Gene Delivery (NVGD) Using Polymeric-Nano Particles

Daikyo Crystal Zenith Cartridges

European Center Of Excellence For Clinical Biologics